131 related articles for article (PubMed ID: 17339865)
1. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
Masci P; Olencki T; Wood L; Rybicki L; Jacobs B; Williams B; Faber P; Bukowski R; Tong K; Borden EC
Clin Pharmacol Ther; 2007 Mar; 81(3):354-61. PubMed ID: 17339865
[TBL] [Abstract][Full Text] [Related]
2. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Post AB; Redfield RR; Davis GL; Neumann AU; Osborn BL; Freimuth WW; Subramanian GM
Antivir Ther; 2006; 11(1):35-45. PubMed ID: 16518958
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM;
Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462
[TBL] [Abstract][Full Text] [Related]
5. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies.
Ohno R; Yamaguchi Y; Toge T; Kinouchi T; Kotake T; Shibata M; Kiyohara Y; Ikeda S; Fukui I; Gohchi A; Sugiyama Y; Saji S; Hazama S; Oka M; Ohnishi K; Ohhashi Y; Tsukagoshi S; Taguchi T
Clin Cancer Res; 2000 Jul; 6(7):2661-9. PubMed ID: 10914707
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Lenzi R; Rosenblum M; Verschraegen C; Kudelka AP; Kavanagh JJ; Hicks ME; Lang EA; Nash MA; Levy LB; Garcia ME; Platsoucas CD; Abbruzzese JL; Freedman RS
Clin Cancer Res; 2002 Dec; 8(12):3686-95. PubMed ID: 12473577
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.
Li M; Lu C; Cheng J; Zhang J; Cao C; Xu J; Xu J; Pan H; Zhong B; Tucker S; Wang D
J Gastroenterol Hepatol; 2009 Aug; 24(8):1437-44. PubMed ID: 19486255
[TBL] [Abstract][Full Text] [Related]
10. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.
Dudek AZ; Yunis C; Harrison LI; Kumar S; Hawkinson R; Cooley S; Vasilakos JP; Gorski KS; Miller JS
Clin Cancer Res; 2007 Dec; 13(23):7119-25. PubMed ID: 18056192
[TBL] [Abstract][Full Text] [Related]
11. Phase I evaluation of a synthetic mutant of beta-interferon.
Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
16. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
18. Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer.
Turner PK; Houghton JA; Petak I; Tillman DM; Douglas L; Schwartzberg L; Billups CA; Panetta JC; Stewart CF
Cancer Chemother Pharmacol; 2004 Mar; 53(3):253-60. PubMed ID: 14648016
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and activity of a new recombinant interferon-alpha B/D hybrid in patients with HIV-1 infection.
Frissen PH; Brinkman K; Ten Napel CH; van der Ende IM; van Buuren IA; Boucher CA; Reiss P; Lange JM
Antivir Ther; 1996 Apr; 1(2):89-97. PubMed ID: 11321184
[TBL] [Abstract][Full Text] [Related]
20. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer.
Tagliaferri P; Caraglia M; Budillon A; Marra M; Vitale G; Viscomi C; Masciari S; Tassone P; Abbruzzese A; Venuta S
Cancer Immunol Immunother; 2005 Jan; 54(1):1-10. PubMed ID: 15693134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
